Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7540-7548

  Idogawa, Masashi ^a   Ohashi, Tomoko ^a   Sugisaka, Jun ^a   Sasaki, Yasushi ^a   Suzuki, Hiromu ^a   Tokino, Takashi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; p53; PRIMA 1; ShRNA library

Indexed keywords

BETA GALACTOSIDASE; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; GENETIC SCREENING; HUH 7 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CANCER; MICROARRAY ANALYSIS; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PANC 1 CELL LINE; PANCREAS CANCER; RNA ANALYSIS; RNA INTERFERENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE GENOMIC HYBRIDIZATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907552101     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2272     Document Type: Article

References (24)

1. Vogelstein B, Lane D and Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810):307-310.
2. Brosh R and Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9(10):701-713.
3. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996; 2(9):985-991.
4. Tazawa H, Kagawa S and Fujiwara T. Advances in adenovirus-mediated p53 cancer gene therapy. Expert Opin Biol Ther. 2013; 13(11):1569-1583.
5. Blagosklonny MV. Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessays. 2001; 23(10):947-953.
6. Riley T, Sontag E, Chen P and Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008; 9(5):402-412.
7. Idogawa M, Ohashi T, Sasaki Y, Maruyama R, Kashima L, Suzuki H and Tokino T. Identification and analysis of large intergenic non-coding RNAs regulated by p53 family members through a genome-wide analysis of p53-binding sites. Hum Mol Genet. 2014.
8. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993; 75(4):817-825.
9. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B and Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat Med. 1997; 3(9):1034-1036.
10. Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y and Tokino T. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin Cancer Res. 2009; 15(11):3725-3732.
11. Ohashi T, Idogawa M, Sasaki Y, Suzuki H and Tokino T. AKR1B10, a Transcriptional Target of p53, Is Downregulated in Colorectal Cancers Associated with Poor Prognosis. Mol Cancer Res. 2013; 11(12):1554-1563.
12. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S and Fojo T. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res. 2005; 65(16):7386-7392.
13. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG and Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-288.
14. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG and Andersson PO. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012; 30(29):3633-3639.
15. Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T, Nicholson RI and Hurst HC. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol. 2009; 217(1):32-41.
16. Cyr AR, Kulak MV, Park JM, Bogachek MV, Spanheimer PM, Woodfield GW, White-Baer LS, O'Malley YQ, Sugg SL, Olivier AK, Zhang W, Domann FE and Weigel RJ. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene. 2014.
17. Li H, Watts GS, Oshiro MM, Futscher BW and Domann FE. AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells. Oncogene. 2006; 25(39):5405-5415.
18. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL and Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 2004; 428(6981):431-437.
19. Kanasty R, Dorkin JR, Vegas A and Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. 2013; 12(11):967-977.
20. Chen J and Xie J. Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7:3971-3980.
21. van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget. 2012; 3(6):596-600.
22. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle. 2008; 7(10):1307-1312.
23. Rao B, van Leeuwen IM, Higgins M, Campbel J, Thompson AM, Lane DP and Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010; 1(7):639-650.
24. van Leeuwen IM, Rao B, Sachweh MC and Lain S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle. 2012; 11(9):1851-1861.